Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastatic lung cancer

Lung cancer is one of the most prevalent cancers, and brain metastases significantly worsen the prognosis for patients. We developed an inhalable surfactant-based biomimetic nanoliposome system (MPDOLs) to co-deliver Osimertinib and DNA plasmids to deplete IGF2BP3 expression. To investigate how MPDOLs influence gene expression and therapeutic outcomes by targeting IGF2BP3 and co-delivering Osimertinib, we performed transcriptomic analysis of MPDOL treated Lewis lung cancer cells. Lewis lung cancer cells were obtained from Procell Life Science and Technology Co., Ltd. (Wuhan, China). They were maintained in Dulbecco's modified Eagle’s medium supplemented with 10% FBS and 1% PS and were cultivated in an environment with a 5% CO2 atmosphere at 37 °C. Lewis lung cancer cells were seeded overnight and treated with MPDOLs or PBS for 48 hours. Total RNA was isolated from cultured cells using the TRIzol reagent for RNA sequencing. Agilent 2100 bioanalyzer was used to control quality and NEBNext®UltraTMRNA Library Prep Kit for Illumina® (NEB, USA) was used to generate libraries.